

## Holdings Report

March 2025

### Regnan Global Equity Impact Solutions Fund

ARSN: 645 981 853

#### Fund holdings (as at 31 March 2025)

| Security ID | Security Name                            |
|-------------|--|
| BP7RS59     | Advanced Drainage Systems Inc            |
| BKF9D57     | Afya Ltd                                 |
| 2520153     | Agilent Technologies Inc                 |
| 2045623     | ANSYS Inc                                |
| BP8JT73     | ATS Corp                                 |
| BFMLGR4     | Autolus Therapeutics PLC                 |
| 2069128     | Badger Meter Inc                         |
| 6709099     | Bank Rakyat Indonesia Persero Tbk PT     |
| BDZRDG3     | Befesa SA                                |
| 5922961     | Carl Zeiss Meditec AG                    |
| 5119901     | Duerr AG                                 |
| 2304227     | Ecolab Inc                               |
| B9HHD96     | HA Sustainable Infrastructure Capital In |
| 6437947     | Horiba Ltd                               |
| B1XGNW4     | Insulet Corp                             |
| 2471949     | Itron Inc                                |
| B00ZC75     | Kardex Holding AG                        |
| 7333378     | Lonza Group AG                           |
| B1YWR63     | Masimo Corp                              |
| BK93ZN7     | Medley Inc                               |
| B01Z7J1     | Monolithic Power Systems Inc             |
| BKM4S16     | MSA Safety Inc                           |
| B95N910     | PTC Inc                                  |
| BNXJZX2     | QIAGEN NV                                |
| BYZ2QP5     | Sartorius Stedim Biotech                 |
| 2750206     | Savaria Corp                             |
| 2854238     | Stantec Inc                              |
| BNM0752     | Stevanato Group SpA                      |
| BLD5321     | Stride Inc                               |
| B8P59C0     | Syncona Ltd                              |
| BPLXRG7     | TOMRA Systems ASA                        |
| BFH3N85     | Veeva Systems Inc                        |
| B4P9W92     | Verisk Analytics Inc                     |
| BFXX5X8     | Verra Mobility Corp                      |
| B3P2CN8     | Xylem Inc/NY                             |
| B0SDJB4     | Zealand Pharma A/S                       |



CERTIFIED BY RIAA

The Regnan Global Equity Impact Solutions Fund has been certified by the Responsible Investment Association Australasia according to the strict operational and disclosure practices required under the Responsible Investment Certification Program. See [www.responsiblereturns.com.au](http://www.responsiblereturns.com.au) for details.

The Responsible Investment Certification Program does not constitute financial product advice. Neither the Certification Symbol nor RIAA recommends to any person that any financial product is a suitable investment or that returns are guaranteed. Appropriate professional advice should be sought prior to making an investment decision. RIAA does not hold an Australian Financial Services Licence.

For more information please,  
contact your key account manager or visit [regnan.com](http://regnan.com)

This report has been prepared by Pandal Fund Services Limited (PFSL) ABN 13 161 249 332, AFSL No 431426 and the information contained within is current as at the date of this report. It is not to be published, or otherwise made available to any person other than the party to whom it is provided.

PFSL is the responsible entity of, and issuer of units in, the Fund offered in this report. A product disclosure statement (PDS) is available for the Fund and can be obtained by calling 1300 346 821 or visiting [www.pandalgroup.com](http://www.pandalgroup.com). The Target Market Determination (TMD) for the Fund is available at [www.pandalgroup.com/ddo](http://www.pandalgroup.com/ddo). You should obtain and consider the PDS and TMD before deciding whether to acquire, continue to hold or dispose of units in the Fund. An investment in the Fund is subject to investment risk, including possible delays in repayment of withdrawal proceeds and loss of income and principal invested.

This report is for general information purposes only, should not be considered as a comprehensive statement on any matter and should not be relied upon as such. It has been prepared without taking into account any recipient's personal objectives, financial situation or needs. Because of this, recipients should, before acting on this information, consider its appropriateness having regard to their individual objectives, financial situation and needs. This information is not to be regarded as a securities recommendation.

The information in this report may contain material provided by third parties, is given in good faith and has been derived from sources believed to be accurate as at its issue date. While such material is published with necessary permission, and while all reasonable care has been taken to ensure that the information in this report is complete and correct, to the maximum extent permitted by law neither PFSL nor any company in the Pandal group accepts any responsibility or liability for the accuracy or completeness of this information.